Thymosin Alpha-1
Research OnlyA 28-amino acid immunomodulatory peptide approved in over 35 countries including China and Italy for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency. Extensive human clinical trial data spanning decades with strong evidence for immune enhancement.
Ta1 · Thymalfasin · Zadaxin · TMSB1
28 human studies
- Preclinical
- 33%
- Clinical
- 67%
Based on 42 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth: meta-analyses of multiple RCTs exist (COVID-19 SR/MA, sepsis Phase 3 TESTS n=1106, ETASS n=361), >1,000 human subjects, but pooled estimates are heterogeneous. Mechanism: TLR2/TLR9 targets with functional confirmation and a largely mapped MyD88-NF-kB pathway to T-cell maturation. Plausibility: mechanism-to-surrogate (mHLA-DR, CD4, cytokines) is solid and coherent with immunology; surrogate-to-mortality link is only partially supported. Global Coverage: independently replicated across many countries with 35+ national regulatory registrations (Zadaxin). Community Experience: sustained >7-year real-world clinical use abroad, broadly consistent well-tolerated reports - a usage signal, not efficacy. Effectiveness basis is clinical (Basis A) but confidence is low: positive mortality signals (COVID-19 RR 0.59, sepsis ETASS RR 0.74) are undercut by the large, rigorous, null TESTS Phase 3 trial (HR 0.99) and high between-trial heterogeneity.
Thymosin alpha-1 is a pleiotropic immunomodulator that enhances both innate and adaptive immunity through multiple pathways.
How It Works (Simplified)
Thymosin alpha-1 acts as an “immune training officer” that enhances multiple arms of the immune system:
Promotes T-cell maturation via TLR signaling on dendritic cells, helping immature T-cells develop into functional soldiers that recognize and attack pathogens and cancer.
Increases MHC class II expression and antigen presentation, making dendritic cells more effective at identifying threats and alerting the immune system.
Increases IL-2, IL-12, and IFN-gamma while modulating inflammatory cytokines - providing immune enhancement without hyperactivation.
Boosts natural killer cell proliferation and cytotoxic activity, enhancing the innate immune system’s rapid response to infected or cancerous cells.
Key Research: Romani L et al. (2004) showed that thymosin alpha-1 activates dendritic cells for Th1 immunity through Toll-like receptor and MyD88-dependent signaling. PMID:14982877
Important Limitations
- Not FDA-approved despite extensive clinical data and 35+ country approvals
- Most large trials are manufacturer-sponsored (SciClone Pharmaceuticals)
- Requires injection administration (subcutaneous, typically twice weekly)
- Effects depend on functional immune system capacity
Reported positives
- Immune system support reported during illness
- Used clinically in 35+ countries as Zadaxin
- Well-tolerated with minimal reported side effects
- Enhanced vaccine response noted in some reports
Reported negatives
- Expensive through compounding pharmacies
- Effects difficult to subjectively measure
- Not FDA-approved in the US despite global approval
- Autoimmune concerns with chronic immune stimulation
“Growing interest in immune optimization community. Global approval in 35+ countries adds credibility.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on clinical trials: Initial immune system modulation begins. T-cell maturation and dendritic cell activation observed. In hepatitis trials, immune markers begin to change within first 2 weeks.
PMID:21227010Immune enhancement effects become more pronounced. Clinical trials showed increased CD4+ T-cell counts and improved cytokine profiles. In hepatitis B trials, viral load reduction may begin.
PMID:21227010Studies show sustained immune enhancement with continued administration. Hepatitis B/C trials demonstrated viral response improvements over 24-52 weeks of treatment.
PMID:18078676Long-term studies in hepatitis and cancer adjuvant therapy show maintained immunomodulatory effects. In countries where approved, treatment courses of 6-12 months are common.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
LL-37
SynergisticBoth enhance innate immunity through complementary mechanisms - Ta1 via T-cell and dendritic cell activation, LL-37 via direct antimicrobial effects.
TB-500
CompatibleDespite both being thymosin-derived, they have distinct functions - Ta1 is immunomodulatory while TB-500 focuses on tissue repair via actin regulation.
BPC-157
CompatibleImmune enhancement from Ta1 may support tissue healing processes promoted by BPC-157, potentially beneficial in infection-prone wound scenarios.
Epithalon
CompatibleBoth developed by Russian researchers for different anti-aging targets - Ta1 for immune restoration, epithalon for telomere maintenance.
Selank
CompatibleBoth have immunomodulatory components - Ta1 as primary function, Selank as secondary effect from tuftsin backbone.
GHK-Cu
CompatibleTa1's immune support may enhance wound healing environments where GHK-Cu promotes collagen synthesis and tissue regeneration.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymosin Alpha-1
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin · hCAP18 · Human Cationic Antimicrobial Peptide 18 +3
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.